奥精医疗一年一期扣非亏损 2021年上市募5.48亿元

Financial Performance - In 2024, the company reported total revenue of 206.03 million yuan, a decrease of 9.03% year-on-year [1] - The net profit attributable to shareholders was -12.66 million yuan, compared to a profit of 54.23 million yuan in the previous year, representing a decline of 123.35% [1] - The net profit after deducting non-recurring gains and losses was -28.37 million yuan, down 210.11% from 25.77 million yuan in the previous year [1] - The net cash flow from operating activities was -19.60 million yuan, a significant drop from 51.68 million yuan in the previous year, indicating a decrease of 137.93% [1] Q1 2025 Performance - For the first quarter of 2025, the company achieved revenue of 42.46 million yuan, down 10.35% year-on-year [2] - The net profit attributable to shareholders was 1.04 million yuan, a decline of 84.99% compared to 6.94 million yuan in the same period last year [2] - The net profit after excluding non-recurring gains and losses was -2.34 million yuan, a decrease of 168.21% from 3.43 million yuan in the previous year [2] - The net cash flow from operating activities was -15.33 million yuan, worsening from -2.09 million yuan in the same period last year, reflecting a change of 633.48% [2] Company Background - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on May 21, 2021, with an initial public offering of 33.33 million shares at a price of 16.43 yuan per share [2] - The total funds raised amounted to 548 million yuan, with a net amount of 501 million yuan after deducting issuance costs [2] - The actual net amount raised was 288 million yuan less than the planned 789 million yuan, which was intended for various projects including the construction of a health technology industrial park [3] Management and Control - The actual controllers of the company are Eric Gang Hu, Cui Fuzhai, and Huang Wanlan, with Eric Gang Hu being a U.S. national and the other two being Chinese nationals without permanent residency abroad [3]